| 26.675 -0.725 (-2.65%) | 04-20 13:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.77 | 1-year : | 38.28 |
| Resists | First : | 28.06 | Second : | 32.77 |
| Pivot price | 26.17  |
|||
| Supports | First : | 22.52 | Second : | 19.11 |
| MAs | MA(5) : | 26.8 |
MA(20) : | 25.19 |
| MA(100) : | 26.16 |
MA(250) : | 31.51 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 82.4 |
| RSI | RSI(14): 57.5 |
|||
| 52-week | High : | 48.45 | Low : | 19.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AAPG ] has closed below upper band by 40.1%. Bollinger Bands are 4.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.89 - 27.97 | 27.97 - 28.06 |
| Low: | 27.15 - 27.25 | 27.25 - 27.36 |
| Close: | 27.22 - 27.37 | 27.37 - 27.54 |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Mon, 20 Apr 2026
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - What's Next? - MarketBeat
Mon, 20 Apr 2026
Ascentage Pharma (NASDAQ: AAPG) showcases four AACR 2026 preclinical studies - Stock Titan
Sun, 19 Apr 2026
Leukemia drug tested beyond CML in 4 cancer combination studies - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 284 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.09 |
| Profit Margin | -216.5 % |
| Operating Margin | -193.4 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -154.6 % |
| Qtrly Rev. Growth | 117 % |
| Gross Profit (p.s.) | 5.62 |
| Sales Per Share | 6.15 |
| EBITDA (p.s.) | -12.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -13.02 |
| PEG Ratio | 0 |
| Price to Book value | 12.7 |
| Price to Sales | 4.33 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|